JBR supported University Medical Center Utrecht with financial analyses of the possible carve-out of the oncology activities.
To make healthcare future-proof, improve quality and keep healthcare affordable, various measures are being taken within the cure sector. Market parties, insurers and the government have agreed that the cure sector will be allowed to grow by a maximum of 1% per year from 2015 to 2017, partly through greater concentration of highly complex care. In order to make the care more transparent and efficient, the hospital sector has switched to a new financing system. From 2012 the hospital sector switched to 70% free pricing and the new DOT declaration system was introduced for hospitals, replacing the 30,000 DBCs with 4,400 new cross-specialty DBC care products (DOTs).
Partly as a result of the new financing, the hospital sector will change significantly in the coming years. This will affect the extent and type of care provided at each location. The new financing system has the necessary influence on the administration of hospitals. The University Medical Center Utrecht (UMC Utrecht) is one of the largest public healthcare institutions in the Netherlands, with eleven divisions. These include dermatology and oncology. The UMC wanted more insight into the cost prices of the various departments. At that time it was not yet entirely clear how the DOT system would affect the budget. For effective management of the organization and the implementation of improvements, insight into various productivity ratios was also needed, preferably in comparison with other similar departments.
JBR supported University Medical Center Utrecht with financial analyses and mapped out the impact of the possible carve-out of the oncology activities.
JBR mapped out the situation together with the client and developed financial models per department, providing insight into cash flows per department, effects of the transition to DOT and input for improving cost analyses. In addition, JBR provided insight into the consequences of a possible carve-out of oncology.